Monitoring of Cytomegalovirus-Specific CD8+ T-Cell Response With Major Histocompatibility Complex Pentamers in Kidney Transplant Recipients

2011 ◽  
Vol 43 (7) ◽  
pp. 2636-2640 ◽  
Author(s):  
S. Lee ◽  
J.B. Park ◽  
E.Y. Kim ◽  
S.Y. Joo ◽  
E.C. Shin ◽  
...  
Keyword(s):  
Major Histocompatibility Complex ◽  
T Cell ◽  
Kidney Transplant ◽  
Cell Response ◽  
Cd8 T Cell ◽  
T Cell Response ◽  
Transplant Recipients ◽  
Major Histocompatibility ◽  
Kidney Transplant Recipients ◽  
Histocompatibility Complex

scholarly journals T cell response specificity and magnitude against SIVmac239 are not concordant in major histocompatibility complex-matched animals

Retrovirology ◽  
2013 ◽  
Vol 10 (1) ◽  
pp. 116 ◽  
Author(s):  
Brian T Cain ◽  
Ngoc H Pham ◽  
Melisa L Budde ◽  
Justin M Greene ◽  
Jason T Weinfurter ◽  
...  
Keyword(s):  
Major Histocompatibility Complex ◽  
T Cell ◽  
Cell Response ◽  
T Cell Response ◽  
Major Histocompatibility ◽  
Histocompatibility Complex ◽  
Response Specificity

scholarly journals CD8+ T cell response to Mls-1a determinants involves major histocompatibility complex class II molecules.

1991 ◽  
Vol 173 (3) ◽  
pp. 779-782 ◽  
Author(s):  
Y Chvatchko ◽  
H R MacDonald
Keyword(s):  
Major Histocompatibility Complex ◽  
T Cell ◽  
Mhc Class Ii ◽  
T Cell Responses ◽  
Cd8 T Cell ◽  
Class Ii ◽  
T Cell Response ◽  
Major Histocompatibility ◽  
Cell Responses ◽  
Histocompatibility Complex

Recent studies indicate that both CD4+ and CD8+ T lymphocytes proliferate in vitro in response to Mls-1a-encoded determinants. Using both immunogenetic and antibody blocking approaches we show here that Mls-1a responses of both subsets require expression of major histocompatibility complex (MHC) class II molecules (I-A and/or I-E) by the stimulator cells. Furthermore, CD8+ T cell responses to Mls-1a/class II MHC do not require (and are in fact inhibited by) the presence of functional CD8 molecules. Taken together, our data underscore the dramatic differences between CD8+ T cell responses to conventional peptide antigens as opposed to "superantigens" such as Mls-1a.

scholarly journals Comparing Humoral and Cellular Adaptive Immunity during Convalescent Phase of COVID-19 in Hemodialysis Patients and Kidney Transplant Recipients

2021 ◽  
Vol 10 (21) ◽  
pp. 4833
Author(s):  
Dorota Kamińska ◽  
Hanna Augustyniak-Bartosik ◽  
Katarzyna Kościelska-Kasprzak ◽  
Marcelina Żabińska ◽  
Dorota Bartoszek ◽  
...  
Keyword(s):  
Immune Response ◽  
T Cell ◽  
Kidney Transplant ◽  
Adaptive Immunity ◽  
Cell Response ◽  
Cellular Response ◽  
T Cell Response ◽  
Interferon Gamma Release Assay ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Background. It is still unclear whether COVID-19 convalescent kidney transplant recipients (KTR) and hemodialysis (HD) patients can develop anti-SARS-CoV-2 adaptive immunity. The aim was to characterize and compare the immune response to the virus in HD patients and KTR. Methods. The study included 26 HD patients and 54 KTR—both convalescent (14 HD, 25 KTR) and unexposed. The immune response was assessed by determining the anti-SARS-CoV-2 antibodies in serum and specific T cell response via the interferon-gamma release assay (IGRA). Moreover, blood-morphology-derived parameters, immune cell phenotypes, and acute phase reactants were evaluated. Results. KRT and HD convalescents presented similar serum levels of anti-SARS-CoV-2 IgG and IgA. A negative correlation occurred between IgG and time after the infection was observed. There was a strong relationship between the prevalence of anti-SARS-CoV-2 cellular and humoral responses in both groups. Convalescent IGRA response was significantly higher in HD patients compared to KTR. Conclusions. HD patients and KTR develop humoral and cellular responses after COVID-19. The antibodies levels are similar in both groups of patients. SARS-CoV-2-reactive T cell response is stronger in HD patients compared to KTR. The SARS-CoV-2-specific IgG level decreases with time while IgA and a cellular response are maintained. IGRA proved to be a valuable test for the assessment of specific cellular immunity in immunocompromised HD patients and KTR.

scholarly journals Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients

2021 ◽  
pp. ASN.2021040480
Author(s):  
Dominique Bertrand ◽  
Mouad Hamzaoui ◽  
Veronique Lemée ◽  
Julie Lamulle ◽  
Melanie Hanoy ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Kidney Transplant ◽  
Cell Response ◽  
Cellular Response ◽  
Hemodialysis Patients ◽  
T Cell Response ◽  
High Rate ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Background. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a high rate of mortality in patients with end stage renal disease and vaccination is hoped to prevent infection. Methods. Between January 18, and February 24, 2021, 225 kidney transplant recipients (KTR) and 45 hemodialysis patients (HDP) received two injections of mRNA BNT162b2 vaccine. The post-vaccinal humoral and cellular response was explored in the first 45 KTR and 10 HDP. Results. After the second dose, 8 HDP (88.9%) and 8 KTR (17.8%) developed anti-spike SARS-CoV-2 antibodies (p<0.0001). Median titer of antibodies in responders was 1052 AU/mL (IQR: 515-2689) in HDP and 671 AU/mL (IQR: 172-1523) in KTR (p=0.4). Nine HDP (100%) and 26 KTR (57.8%) showed a specific T cell response (p=0.06) after the second injection. In responders, median numbers of spike-reactive T cells were 305 SFC/106 CD3+ T cells (IQR: 95-947) in HDP and 212 SFC/106 CD3+ T cells (IQR: 61-330) in KTR (p=0.4). In KTR, the immune response to BNT162b2 seemed influenced by the immunosuppressive regimen, particularly tacrolimus or belatacept. Conclusion. Immunization with BNT162b2 seems more efficient in HDP, indicating that vaccination should be highly recommended in these patients awaiting a transplant. However, the current vaccinal strategy for KTR may not provide effective protection against COVID-19 and will likely need to be improved.

Structural basis for a major histocompatibility complex class Ib–restricted T cell response

2006 ◽  
Vol 7 (3) ◽  
pp. 256-264 ◽  
Author(s):  
Hilary L Hoare ◽  
Lucy C Sullivan ◽  
Gabriella Pietra ◽  
Craig S Clements ◽  
Eleanor J Lee ◽  
...  
Keyword(s):  
Major Histocompatibility Complex ◽  
T Cell ◽  
Major Histocompatibility Complex Class ◽  
Cell Response ◽  
T Cell Response ◽  
Structural Basis ◽  
Complex Class ◽  
Major Histocompatibility ◽  
Histocompatibility Complex ◽  
Class Ib

scholarly journals Antibody and T cell response to a third dose of SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients.

2021 ◽  
Author(s):  
Dominique Bertrand ◽  
Mouad Hamzaoui ◽  
Veronique Lemée ◽  
Julie Lamulle ◽  
Charlotte Laurent ◽  
...  
Keyword(s):  
T Cell ◽  
Kidney Transplant ◽  
Cell Response ◽  
Messenger Rna ◽  
T Cell Response ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document